Darell Bigner
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Darell Bigner sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Darell Bigner: 6 sponsored US clinical trials, 4 recruiting.
Darell Bigner sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Newly Diagnosed MGMT Unmethylated Glioblastoma, with 1 trials.
Upper-quartile sponsor footprint
Darell Bigner sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
NCT06455605
Lerapolturev (PVSRIPO) in GBM
NCT06177964
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
NCT05734560
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
NCT04547777
D2C7-IT With Atezolizumab for Recurrent Gliomas
NCT04160494
D2C7 for Adult Patients With Recurrent Malignant Glioma
NCT02303678
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
What is open in the Darell Bigner pipeline
4 recruiting of 6 indexed (67% open); 1 completed (17%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Newly Diagnosed MGMT Unmethylated Glioblastoma (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Darell Bigner: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Darell Bigner sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Darell Bigner page
6 registered trials is a research-attention snapshot, not an endorsement of Darell Bigner or any single study.
- 4 of Darell Bigner's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Newly Diagnosed MGMT Unmethylated Glioblastoma is the condition Darell Bigner studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Newly Diagnosed MGMT Unmethylated Glioblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Darell Bigner pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.